Stock Ratings / Health Care / SPRY / dividends

RLMD (44) EBS (53) CYPH (40) GALT (42) ⌘ Pro Terminal →

ARS Pharmaceuticals Inc. (SPRY) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is SPRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $3.66 (+0.27% 1D, market cap $364.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SPRY ranks #978 in composite RQD confidence.

Q: How does SPRY compare to RLMD and EBS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRY carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $366.9M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (53/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for SPRY?

Per SPRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671858), ARS Pharmaceuticals Inc. generated $84.3M in revenue (-5.5% YoY), -$171.3M in net income, and -$171.2M in free cash flow against $327.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is SPRY trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRY last traded at $3.66 (+0.27% on volume of 2,044,382 shares), positioning the stock -19.91% below its 50-day simple moving average ($4.57) and -50.47% below its 200-day simple moving average ($7.39). Across its 52-week range of $3.34 to $13.15, SPRY sits at the 3.3% percentile with a 14-day RSI of 29.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.20 to $4.12).

Q: Does SPRY pay a dividend and is it safe?

ARS Pharmaceuticals Inc. (SPRY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$3.66 +0.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.65

ARS Pharmaceuticals Inc. (SPRY) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $364.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.65 (-0.14%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPRY)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY SPRY SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (30% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 29.8 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.23-5% Next Q

Q2 (-2Q)

Grade E$4.02+0.2% Next Q

Q3 (-1Q)

Grade E$4.03-9.2% Next Q

Current

Grade E$3.66-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SPRY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SPRY currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.57) and Max Pain ($3.84) forces dealer call-delta covering toward $13.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SPRY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SPRY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPRY)

✓Walkthrough of SPRY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SPRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.69%⚡ TESTING RESISTANCE

2026-10-30O $3.62H $3.79L $3.34C $3.66VOL 1.75M

RES: $3.75SUP: $2.39SMA50: $4.57SMA200: $7.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPRY Butterfly Map → + Track SPRY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -5.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SPRY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPRY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SPRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPRY)

Health Care Rank #978 of 1016 ⚔️ RLMD vs SPRY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPRY vs. RLMD, EBS, CYPH, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ARS Pharmaceuticals Inc. (SPRY) ranks #978 by composite RQD confidence (27/100, grade E) and #496 by equity capitalization ($364.0M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with SPRY at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SPRY ACTIVE ARS Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	+0.27%	$364.0M	Benchmark Subject
RLMD Relmada Therapeutics Inc.	D	44/100	—	—	-35.0%	+2.69%	$366.9M	/rlmd-vs-spry →
EBS Emergent BioSolutions Inc.	D+	53/100	7.0x	56.1%	8.9%	+1.83%	$370.2M	/ebs-vs-spry →
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-spry →
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-spry →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671858

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ARS Pharmaceuticals Inc. (SPRY) reported GAAP revenue of $84.3M (-5.5% vs. FY2024 revenue of $89.1M , and +280826.7% cumulative change since FY2023) , GAAP net income of -$171.3M, operating cash flow of -$170.9M, and free cash flow of -$171.2M (-1418.5% YoY). On the balance sheet, SPRY closed FY2025 with $327.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$84.3M	-$171.3M	-$170.9M	-$171.2M	$327.7M	—
FY2024 (FY)	2024-12-31	$89.1M	$8.0M	$13.5M	$13.0M	$351.2M	—
FY2023 (FY)	2023-12-31	$30.0K	-$54.4M	-$59.3M	-$59.3M	—	—

3. SPRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $3.66 (+0.27% 1D, market cap $364.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SPRY ranks #978 in composite RQD confidence.

How does SPRY compare to RLMD and EBS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRY carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $366.9M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (53/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SPRY?

Per SPRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671858), ARS Pharmaceuticals Inc. generated $84.3M in revenue (-5.5% YoY), -$171.3M in net income, and -$171.2M in free cash flow against $327.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SPRY trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRY last traded at $3.66 (+0.27% on volume of 2,044,382 shares), positioning the stock -19.91% below its 50-day simple moving average ($4.57) and -50.47% below its 200-day simple moving average ($7.39). Across its 52-week range of $3.34 to $13.15, SPRY sits at the 3.3% percentile with a 14-day RSI of 29.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.20 to $4.12).

SPRY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SPRY pay a dividend and is it safe?

ARS Pharmaceuticals Inc. (SPRY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SPRY RQD Cockpit SPRY 12M Forecast SPRY Earnings & Move SPRY Dividends & DRIP SPRY Insiders & 13F SPRY Whale Options SPRY Profit Sankey SPRY News & Why